Drug
Gadobutrol clinical trials
Also written Gadavist and GADOVIST.
- studies test it
- 20
- open now
- 1
- in phase 3
- 13
- first study started
- 2006
Keep track of what changes. Save the gadobutrol studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
20 studies that test it; most in 2010 (3)
| Year | Studies |
|---|---|
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 3
- 13
- Phase 4
- 4
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 4
Bayer (14) · Northwestern University (1) · University of Massachusetts, Worcester (1) · Guerbet (1) · Bracco Diagnostics, Inc (1) · M.D. Anderson Cancer Center (1) · University of Southern California (1)
Often tested with
Tested in the same studies.
Gadobenic acid (2) · Gadoteridol (1) · Gadoterate meglumine (1) · Gadopiclenol (1)
Studies
Open first, then newest update. How each study uses gadobutrol is read from its arms, and is right about nine times in ten.
Testing it · 20
- Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal DiseaseRecruitingNot applicableM.D. Anderson Cancer CenterNCT07415018Written as Gadavist
- Investigational MRI Clinical Software and HardwareActive, not recruitingPhase 4Northwestern UniversityNCT05215132Written as Gadavist 2Ml Solution for Injection
- Dotarem vs Gadobutrol Contrast for Breast MRICompletedPhase 4University of Massachusetts, WorcesterNCT03730051Written as Gadobutrol
- Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)CompletedPhase 1BayerNCT01544166Written as Gadobutrol (Gadavist, BAY86-4875)
- Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)CompletedPhase 3BayerNCT01890434Written as Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- Gadobutrol Enhanced MRA of the Supra-aortic VesselsCompletedPhase 3BayerNCT01344447Written as Gadobutrol (Gadovist, BAY86-4875)
- Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)CompletedPhase 3BayerNCT01890421Written as Gadobutrol (Gadovist, Gadavist, BAY86-4875)
- SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative StudyCompletedPhase 3BayerNCT00522951Written as Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain MetastasesTerminatedNot applicableUniversity of Southern CaliforniaNCT02967380Written as Gadobutrol
- Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain TumorsCompletedPhase 4GuerbetNCT02034708Written as Gadovist®/Gadavist®
- Gadobutrol Enhanced MRA of the Renal ArteriesCompletedPhase 3BayerNCT01344460Written as Gadobutrol (Gadovist, BAY86-4875)
- Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese PatientsCompletedPhase 3BayerNCT00395460Written as Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- Gadobutrol Magnevist-controlled Body StudyCompletedPhase 3BayerNCT01050829Written as Gadobutrol (Gadovist, BAY86-4875)
- Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) ImagingCompletedPhase 3BayerNCT00709852Written as Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRICompletedPhase 3BayerNCT01067976Written as Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)CompletedPhase 3BayerNCT01104584Written as Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS ImagingCompletedPhase 3BayerNCT01660841Written as Gadobutrol (Gadovist, BAY86-4875)
- Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) ImagingCompletedPhase 3BayerNCT00623467Written as Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese PatientsCompletedPhase 3BayerNCT00395733Written as Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- Study to Compare MultiHance With Gadovist in Magnetic Resonance Imaging (MRI) of the BrainCompletedPhase 4Bracco Diagnostics, IncNCT00907530Written as GADOVIST
Given in every arm · 1 — gadobutrol is usual care beside what is tested
As the comparator · 1 — what is tested is compared with gadobutrol
Codes
What other systems call gadobutrol · ClinicalTrials.gg INT003815
- MeSH (NLM) C090600gadobutrolConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 1BJ477IO2LGADOBUTROLConfirmed FDA, NLM
- RxNorm 84990One source FDA
- NCI Thesaurus C70675GadobutrolOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C090600 | gadobutrol | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 1BJ477IO2L | GADOBUTROL | Confirmed FDA, NLM |
| RxNorm | 84990 | — | One source FDA |
| NCI Thesaurus | C70675 | Gadobutrol | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.